X
KEY PRODUCTS
Contact email: customerservice@curiaglobal.com
Sales Offices:
ITALY
Rozzano - Quinto de’ Stampi
Via Volturno, 41/43
20089 - Rozzano (MI) - Italy
Tel: +39 02 822 72 1
SPAIN
Parque Tecnológico, Parcela 105
47151 Boecillo, Valladolid, Spain
Tel: +34 983 54 80 72
JAPAN
Level 28 Shinagawa Intercity Tower A
2-15-1 Konan Minato-ku
Tokyo 108-6028, Japan
Tel: +81 3 6717 2807
CHINA
Shanggu Commercial Center A-601
Tian Ta Street, Nankai District
Tianjin 300381, China
Tel: +86 22 23412321
INDIA
713, Exim Link Building
Opp. Indira Container Yard
Mulund – Goregoan Link Road, Nahur (W)
Mumbai – 400078, India
Tel: 022 67250230-31
API Manufacturing Sites
UNITED STATES
RENSSELAER
33 Riverside Avenue
Rensselaer, New York 12144 USA
ALBANY
21 Corporate Circle
Albany, New York 12203 USA
GRAFTON
870 Badger Circle
Grafton, Wisconsin 53024 USA
SPRINGFIELD
2460 West Bennett Street
Springfield, Missouri 65807 USA
FRANCE
BON ENCONTRE
Zone Industrielle de Laville
F-47240 - Bon-Encontre - France
TONNEINS
Avenue du Dr Nicole Bru
F-47400 - Tonneins - France
GERMANY
FRANKFURT
Industriepark Höchst
65926 - Frankfurt - Germany
ITALY
ROZZANO - Quinto de’ Stampi
Via Volturno, 41/43
20089 - Rozzano (MI) - Italy
ROZZANO - Valleambrosia
Via Monterosa, 114
20089 - Rozzano (MI) - Italy
ORIGGIO
Viale Europa, 5
21040 - Origgio (VA) - Italy
SPAIN
VALLADOLID
Parque Tecnológico, Parcela 105
47151 Boecillo, Valladolid, Spain
INDIA
AURANGABAD
Curia India Pvt. Ltd.
G-1/1, 1/2, MIDC Area
Waluj, Aurangabad 431 136
(Maharashtra), India
AURANGABAD
Finkem Laboratories Pvt. Ltd.
G-39/5, MIDC Area
Waluj, Aurangabad 431 136
(Maharashtra), India
Details:
Murine monoclonal antibodies have the potential for neutralizing a broader spectrum of SARS-CoV-2 variants and to generate high affinity antibodies that recognize different epitopes on the SARS-CoV-2 spike protein.
Lead Product(s): Murine Monoclonal Antibody
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Tonix Pharmaceuticals Holding Corp
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement December 12, 2022
Details:
IHL-216A (cannabidiol) has been observed to have a greater neuroprotective effect in a rodent model of sports concussion than CBD, and results indicate restoration of the spatial memory deficit post-concussion with IHL-216A administration.
Lead Product(s): Cannabidiol,Isoflurane
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: IHL-216A
Highest Development Status: PreclinicalProduct Type: Small molecule
Recipient: Incannex Healthcare
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement August 02, 2022
Details:
Denovo discovered a novel genetic biomarker for DB104 (liafensine) efficacy using its unique machine learning approach with whole genome sequencing to identify biomarkers that may be predictive of a patient's response to a specific medicine.
Lead Product(s): Liafensine
Therapeutic Area: Psychiatry/Psychology Product Name: DB104
Highest Development Status: Phase IIProduct Type: Small molecule
Recipient: Denovo Biopharma
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 28, 2022
Details:
As part of the collaboration, Curia’s experienced process development team will support the GMP production of Replicate Bioscience’s srRNA vectors up to eight-liter scale (8L), which can be used in Phase 1 through pivotal clinical trials.
Lead Product(s): srRNA Therapeutic
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Replicate Bioscience
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration June 09, 2022
Details:
Curia has been named as the exclusive supplier of the active pharmaceutical ingredient (API) in Cassiopea SpA’s (SIX: SKIN) recently approved acne treatment, Winlevi® (clascoterone) cream 1%.
Lead Product(s): Clascoterone
Therapeutic Area: Dermatology Product Name: Winlevi
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Cassiopea
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement October 30, 2020
Details:
Bryostatin-1 is the company’s lead compound being developed to improve patient outcomes by amplifying the response and increasing the durability of targeted cancer immunotherapies.
Lead Product(s): Bryostatin-1
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Recipient: BryoLogyx Inc
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 13, 2020
Details:
Curia has been chosen to contribute to the supply of the vaccine candidate through sterile fill/finish of AZD1222 at Curia’s drug product manufacturing facility in Albuquerque, New Mexico.
Lead Product(s): ChAdOx1 nCoV-19
Therapeutic Area: Infections and Infectious Diseases Product Name: AZD1222
Highest Development Status: Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: AstraZeneca
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement September 03, 2020
Details:
Curia will provide research, development and cGMP manufacturing of a proprietary psilocybin active pharmaceutical ingredient to support the clinical development of TRP-8802, TRP-8803 and TRP-8804 programs.
Lead Product(s): Psilocybine
Therapeutic Area: Psychiatry/Psychology Product Name: TRP-8802
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Tryp Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership August 13, 2020
Details:
The companies together are undertaking research to investigate the potential of merimepodib to fight SARS-CoV-2, the virus that causes COVID-19, either as a stand-alone treatment or in combination with other antiviral agents or immune modulators.
Lead Product(s): Merimepodib,Remdesivir
Therapeutic Area: Infections and Infectious Diseases Product Name: VX-497
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: BioSig Technologies
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership July 08, 2020
Details:
In return, under a supply agreement, BryoLogyx will supply Neurotrope with specified amounts of synthetic, Bryostatin-1 will be chemically synthesized by Curia in collaboration with BryoLogyx.
Lead Product(s): Bryostatin-1
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: BryoLogyx Inc
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration June 11, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
Curia- A partner for the pharma and biotech industries to improve patient outcomes & quality of life.
